Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


13.02.2017

2 Am J Hematol
7 Ann Hematol
1 Ann Oncol
7 Blood
1 Cancer
1 Cancer Lett
5 Eur J Haematol
2 Exp Hematol
2 Int J Hematol
1 J Pediatr Hematol Oncol
3 Leuk Res
3 Leukemia
1 Oncogene
1 PLoS Biol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. BORATE U, Norris BA, Lo P, Tognon C, et al
    Identification of targeted therapies for rare adult mature t-cell leukemia using functional ex vivo screening of primary patient samples.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24669.
    PubMed     Text format    

  2. SHOUVAL R, Bonifazi F, Fein J, Boschini C, et al
    Validation of the Acute Leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24677.
    PubMed     Text format     Abstract available


    Ann Hematol

  3. CHRISTOPEIT M, Grundhoff A, Rohde H, Belmar-Campos C, et al
    Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing.
    Ann Hematol. 2016;95:1919-21.
    PubMed     Text format    

  4. PARK H, Youk J, Kim I, Yoon SS, et al
    Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Ann Hematol. 2016;95:1777-86.
    PubMed     Text format     Abstract available

  5. THULER LC, Pombo-de-Oliveira MS
    Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012.
    Ann Hematol. 2017;96:355-362.
    PubMed     Text format     Abstract available

  6. GORNICEC M, Wolfler A, Stanzel S, Sill H, et al
    Evidence for a role of decitabine in the treatment of myeloid sarcoma.
    Ann Hematol. 2017;96:505-506.
    PubMed     Text format    

  7. HOLTICK U, Herling M, Pflug N, Chakupurakal G, et al
    Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
    Ann Hematol. 2017;96:479-487.
    PubMed     Text format     Abstract available

  8. PAUBELLE E, Ducastelle-Lepretre S, Labussiere-Wallet H, Nicolini FE, et al
    Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
    Ann Hematol. 2017;96:363-371.
    PubMed     Text format     Abstract available

  9. ZHANG X, Pan J
    Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
    Ann Hematol. 2017 Feb 2. doi: 10.1007/s00277-017-2923.
    PubMed     Text format    


    Ann Oncol

  10. MATO AR, Hill BT, Lamanna N, Barr PM, et al
    Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients.
    Ann Oncol. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format    


    Blood

  11. GODWIN CD, McDonald GB, Walter RB
    Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.
    Blood. 2017 Feb 2. pii: blood-2017-01-762419. doi: 10.1182/blood-2017-01-762419.
    PubMed     Text format    


  12. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45(3):321-334.
    Blood. 2016;128:1995.
    PubMed     Text format    

  13. POLLYEA DA, Jordan CT
    Therapeutic targeting of acute myeloid leukemia stem cells.
    Blood. 2017 Feb 3. pii: blood-2016-10-696039. doi: 10.1182/blood-2016-10-696039.
    PubMed     Text format     Abstract available

  14. HOLYOAKE TL, Vetrie D
    The chronic myeloid leukemia stem cell: stemming the tide of persistence.
    Blood. 2017 Feb 3. pii: blood-2016-09-696013. doi: 10.1182/blood-2016-09-696013.
    PubMed     Text format     Abstract available

  15. THOMAS D, Majeti R
    Biology and relevance of human acute myeloid leukemia stem cells.
    Blood. 2017 Feb 3. pii: blood-2016-10-696054. doi: 10.1182/blood-2016-10-696054.
    PubMed     Text format     Abstract available

  16. CAMPANA D, Pui CH
    Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.
    Blood. 2017 Feb 6. pii: blood-2016-12-725804. doi: 10.1182/blood-2016-12-725804.
    PubMed     Text format    

  17. MILNE TA
    Mouse models of MLL leukemia: recapitulating the human disease.
    Blood. 2017 Feb 8. pii: blood-2016-10-691428. doi: 10.1182/blood-2016-10-691428.
    PubMed     Text format     Abstract available


    Cancer

  18. JAIN P, Thompson PA, Keating M, Estrov Z, et al
    Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30596.
    PubMed     Text format     Abstract available


    Cancer Lett

  19. GAZI M, Moharram SA, Marhall A, Kazi JU, et al
    The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Cancer Lett. 2017 Feb 1. pii: S0304-3835(17)30077.
    PubMed     Text format     Abstract available


    Eur J Haematol

  20. HEHLMANN R
    CML - we are not there yet.
    Eur J Haematol. 2016;97:107.
    PubMed     Text format    

  21. BARON F, Nagler A
    Best allogeneic transplantation approach for AML patients in first CR: is delayed unrelated donor bone marrow transplantation better than immediate unrelated cord blood transplantation?
    Eur J Haematol. 2016 Feb 10. doi: 10.1111/ejh.12745.
    PubMed     Text format     Abstract available

  22. ANSARI J, Naqash AR, Munker R, El-Osta H, et al
    Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment.
    Eur J Haematol. 2016;97:9-16.
    PubMed     Text format     Abstract available

  23. SODERLUND S, Dahlen T, Sandin F, Olsson-Stromberg U, et al
    Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
    Eur J Haematol. 2017;98:57-66.
    PubMed     Text format     Abstract available

  24. GONZALEZ-GASCON Y MARIN I, Martin AA, Hernandez-Sanchez M, Robledo C, et al
    Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL.
    Eur J Haematol. 2017;98:142-148.
    PubMed     Text format     Abstract available


    Exp Hematol

  25. CAO H, Xu Y, de Necochea-Campion R, Baylink DJ, et al
    Application of vitamin D and vitamin D analogs in acute myelogenous leukemia.
    Exp Hematol. 2017 Feb 4. pii: S0301-472X(17)30050.
    PubMed     Text format     Abstract available

  26. CANDONI A, De Marchi F, Zanini F, Zannier ME, et al
    Predictive value of pre transplant molecular minimal residual disease assessment by wt1 gene expression in flt3 positive acute myeloid leukemia.
    Exp Hematol. 2017 Jan 31. pii: S0301-472X(17)30015.
    PubMed     Text format     Abstract available


    Int J Hematol

  27. OGAWA Y, Izutsu K, Kiguchi T, Choi I, et al
    A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.
    Int J Hematol. 2017 Feb 3. doi: 10.1007/s12185-016-2178.
    PubMed     Text format     Abstract available

  28. YOKOYAMA H, Takahashi N, Katsuoka Y, Inomata M, et al
    Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.
    Int J Hematol. 2017 Feb 7. doi: 10.1007/s12185-017-2190.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  29. HORIBE K, Yumura-Yagi K, Kudoh T, Nishimura S, et al
    Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
    J Pediatr Hematol Oncol. 2017 Feb 6. doi: 10.1097/MPH.0000000000000760.
    PubMed     Text format     Abstract available


    Leuk Res

  30. HUANG SJ, Lee LJ, Gerrie AS, Gillan TL, et al
    Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada.
    Leuk Res. 2017;55:79-90.
    PubMed     Text format     Abstract available

  31. MOHAMED AM, Balsat M, Koering C, Maucort-Boulch D, et al
    TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
    Leuk Res. 2017;56:21-28.
    PubMed     Text format     Abstract available

  32. QUAGLIANO A, Gopalakrishnapillai A, Barwe SP
    Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.
    Leuk Res. 2017;56:36-43.
    PubMed     Text format     Abstract available


    Leukemia

  33. COPPE A, Andersson EI, Binatti A, Gasparini VR, et al
    Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach.
    Leukemia. 2017 Feb 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  34. WANG M, Lindberg J, Klevebring D, Nilsson C, et al
    Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
    Leukemia. 2017 Feb 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

  35. DANG J, Nance S, Ma J, Cheng J, et al
    AMKL chimeric transcription factors are potent inducers of leukemia.
    Leukemia. 2017 Feb 8. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    Oncogene

  36. WAKIM J, Arman E, Becker-Herman S, Kramer MP, et al
    The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    PLoS Biol

  37. MAHMOUDI T, Boj SF, Hatzis P, Li VS, et al
    Correction: The Leukemia-Associated Mllt10/Af10-Dot1l Are Tcf4/beta-Catenin Coactivators Essential for Intestinal Homeostasis.
    PLoS Biol. 2017;15:e1002596.
    PubMed     Text format     Abstract available


    PLoS One

  38. SHOU LH, Cao D, Dong XH, Fang Q, et al
    Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
    PLoS One. 2017;12:e0171608.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: